05:52 AM EDT, 04/28/2025 (MT Newswires) -- Pfizer ( PFE ) said Saturday that its investigational drug sasanlimab in combination with standard of care Bacillus Calmette-Guerin as induction and maintenance therapy in patients with high-risk non-muscle invasive bladder cancer met its primary endpoint of event-free survival in a phase 3 trial.

The trial showed a 32% reduction in the risk of disease-related events with the sasanlimab combination regimen as compared with the standard of care treatment alone, the pharmaceutircal giant said.

The probability of being event-free at 36 months was 82.1% with sasanlimab in combination with BCG and 74.8% with BCG alone, the company said.

Sasanlimab in combination with induction-only BCG failed to meet a secondary endpoint of prolongation of event-free survival compared with BCG alone as an induction and maintenance therapy, the company said.

Pfizer ( PFE ) said it has shared study data with health authorities worldwide to support potential regulatory filings.